Literature DB >> 23919956

A rare association of leiomyosarcoma with squamous cell carcinoma of the larynx: two cases.

E Kara1, M F Cetik, U Tuncer, A Uguz.   

Abstract

OBJECTIVE: To discuss the histopathogenesis and treatment choices for synchronous tumours of the larynx. CASE REPORTS: We present two cases of synchronous laryngeal leiomyosarcoma and squamous cell carcinoma. The first case was an early-stage tumour and the second an advanced-stage tumour of the larynx. Selection of adequate treatment for synchronous tumours is difficult because of different spreading rates and metastatic patterns. Treatment choices for both the primary tumour site and the neck should be related to the stage of the squamous component of the tumour.
CONCLUSION: In such cases, the tumour location, tumour stage and lymphatic metastases must be carefully evaluated in order to make the optimum treatment choice. Treatment evaluation of the neck should be related to the stage of the squamous component of these synchronous tumours. Partial laryngectomy techniques may be preferred if the extent of the disease permits.

Entities:  

Mesh:

Year:  2013        PMID: 23919956     DOI: 10.1017/S0022215113001618

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Kissing tumors; the concurrent diagnosis of leiomyosarcoma and squamous cell carcinoma of the esophagus.

Authors:  Hamed Gheibollahi; Amirreza Dehghanian; Negar Taheri; Saeid Tavanafar; Seyede Sona Mousavi; Hamidreza Abbasi; Mohammadreza Sasani
Journal:  BMC Surg       Date:  2021-01-06       Impact factor: 2.102

2.  Leiomyosarcoma of the Tracheostomy Site in a Patient with History of Laryngeal Squamous Cell Carcinoma.

Authors:  Zainub Ajmal; Abdul Moiz Khan; Lezah McCarthy; Allison Lupinetti; Syed Mehdi
Journal:  Case Rep Oncol       Date:  2021-06-17

3.  Incidence and mortality of laryngeal cancer in China, 2008-2012.

Authors:  Yuqin Liu; Qin Zhao; Gaoheng Ding; Yitong Zhu; Wenying Li; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2018-06       Impact factor: 5.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.